Abstract 2503: Three-Year Follow-Up Patients with ST-Segment Elevation Acute Myocardial Infarction Treated with Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent: Multicenter Registry in Asia
Background: Previous clinical study utilizing Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) in simple coronary lesions demonstrated an impressive reduction in intimal hyperplasia and restenosis. However, clinical efficacy of SES and PES in treating patients with ST-segment elevation myocardial infarction (STEMI) has not been validated.
Methods: We assessed baseline clinical and angiographic characteristics, in-hospital and 12, 24 and 36-month major adverse cardiac events (MACE) in 1838 consecutive STEMI patients who received on SES, PES or bare metal stents (BMS) without cardiogenic shock undergoing emergent PCI.
Results: The baseline clinical characteristics between 3 groups were similar. See table⇓ for the clinical results.
Conclusion: Implantation of Sirolimus-eluting stent and Paclitaxel-eluting stent in STEMI patients is not associated with any risk of adverse in-hospital events, and reduced the need for repeat PCI at follow-up.